99-13098. Importation of Controlled Substances; Notice of Application  

  • [Federal Register Volume 64, Number 100 (Tuesday, May 25, 1999)]
    [Notices]
    [Pages 28215-28216]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-13098]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF JUSTICE
    
    Drug Enforcement Administration
    
    
    Importation of Controlled Substances; Notice of Application
    
        Pursuant to section 1008 of the Controlled Substances Import and 
    Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
    issuing a registration under this Section to a bulk manufacturer of a 
    controlled substance in Schedule I or II and prior to issuing a 
    regulation under section 1002(a) authorizing the importation of such a 
    substance, provide manufacturers holding registrations for the bulk 
    manufacture of the substance an opportunity for a hearing.
        Therefore, in accordance with Sec. 1311.42 of Title 21, Code of 
    Federal Regulations (CFR), notice is hereby given that on January 25, 
    1999, Sigma Chemical Company, Subsidiary of Sigma-Aldrich Company, 3500 
    Dekalb Street, St. Louis, Missouri 63118, made application by renewal 
    to the Drug Enforcement Administration to be registered as an importer 
    of the basic classes of controlled substances listed below:
    
    ------------------------------------------------------------------------
                        Drug                               Schedule
    ------------------------------------------------------------------------
    Cathinone (1235)...........................  I
    Methcathinone (1237).......................  I
    Methaqualone (2565)........................  I
    Ibogaine (7260)............................  I
    Lysergic acid diethylamide (7315)..........  I
    Tetrahydrocannabinols (7370)...............  I
    Mescaline (7381)...........................  I
    4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
    3, 4-Methylenedioxyamphetamine (7400)......  I
    3, 4-Methylenedioxy-N-ethylamphetamine       I
     (7404).
    3, 4-Methylenedioxymethamphetamine (7405)..  I
    4-Methoxyamphetamine (7411)................  I
    Psilocyn (7438)............................  I
    Heroin (9200)..............................  I
    Normorphine (9313).........................  I
    Etonitazene (9624).........................  I
    Amphetamine (1100).........................  II
    Methamphetamine (1105).....................  II
    Methylphenidate (1724).....................  II
    Amobarbital (2125).........................  II
    Pentobarbital (2270).......................  II
    Secobarbital (2315)........................  II
    Phencyclidine (7471).......................  II
    Cocaine (9041).............................  II
    Codeine (9050).............................  II
    Oxycodone (9143)...........................  II
    Hydromorphone (9150).......................  II
    Benzoylecogonine (9180)....................  II
    Ethylmorphine (9190).......................  II
    Hydrocodone (9193).........................  II
    Levorphanol (9220).........................  II
    Meperidine (9230)..........................  II
    Methadone (9250)...........................  II
    Dextropropoxyphene, bulk, (non-dosage        II
     forms) (9273).
    Morphine (9300)............................  II
    Thebaine (9333)............................  II
    Opium powdered (9639)......................  II
    Oxymorphone (9652).........................  II
    Fentanyl (9802)............................  II
    ------------------------------------------------------------------------
    
        The firm plans to repackage and offer as pure standards controlled 
    substances in small milligram quantities for drug testing and analysis.
        Any manufacturer holding, or applying for, registration as a bulk 
    manufacturer of these basic classes of controlled substances may file 
    written comments on or objections to the application described above 
    and may, at the same time, file a written request for a hearing on such 
    application in
    
    [[Page 28216]]
    
    accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 
    1316.47. Any such comments, objections, or requests for a hearing may 
    be addressed, in quintuplicate, to the Deputy Assistant Administrator, 
    Office of Diversion Control, Drug Enforcement Administration, United 
    States Department of Justice, Washington, DC 20537, Attention: DEA 
    Federal Register Representative (CCR), and must be filed no later than 
    June 24, 1999.
        This procedure is to be conducted simultaneously with and 
    independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
    (e), and (f). As noted in a previous notice at 40 FR 43745-46 
    (September 23, 1975), all applicants for registration to import the 
    basic classes of any controlled substances in Schedule I or II are and 
    will continue to be required to demonstrate to the Deputy Assistant 
    Administrator, Office of Diversion Control, Drug Enforcement 
    Administration that the requirements for such registration pursuant to 
    21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), 
    (d), (e), and (f) are satisfied.
    
        Dated: May 14, 1999.
    John H. King,
    Deputy Assistant Administrator, Office of Diversion Control, Drug 
    Enforcement Administration.
    [FR Doc. 99-13098 Filed 5-24-99; 8:45 am]
    BILLING CODE 4410-09-M
    
    
    

Document Information

Published:
05/25/1999
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
99-13098
Pages:
28215-28216 (2 pages)
PDF File:
99-13098.pdf